Worldwide, varicose veins is a disease which accounts for 5 million procedures annually and represents a 10 billion USD market. Until now the treatment was done by surgery or so-called minimally invasive techniques. These interventions always present a risk for patients.
Theraclion’s SONOVEIN is non-invasive and makes unnecessary interventions a thing of the past. Their innovation is based on therapeutic ultrasound: High Intensity Focused Ultrasound (HIFU). They are the only player in the market to master the application of this technique in non-deep targets. For patients this means no surgery, no anesthesia, immediate recovery therefore no more surgery-related risk.
Theraclion is established in Europe and Asia. And their ambition, by 2022, is to tackle the US market.